Tier 2 — strong

Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression

Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD
Metabolism: clinical and experimental 2010 59(2):285-292

Bibliography

PubMed
PMID 19800084
DOI
10.1016/j.metabol.2009.07.029
Funding
Funding was not established from the accessible source; this is not a declaration of no funding.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignHuman intervention with separate preclinical experiments
ModelHuman participants; see population
SampleClinical diabetes and hepatitis-related cohorts; exact denominators require full methods
InterventionBerberine with metformin/rosiglitazone comparisons; separate cell experiments
DurationClinical treatment duration not established from abstract
EndpointsFasting and postload glucose; HbA1c and insulin sensitivity; Lipid profile and tolerability

What the study showed, in plain terms

Clinical glucose changes accompanied increased insulin-receptor expression in circulating lymphocytes. Separate cultured-cell experiments explored the receptor pathway.

Key findings

  • Clinical glucose changes accompanied increased insulin-receptor expression in circulating lymphocytes. Separate cultured-cell experiments explored the receptor pathway.

What this study can and cannot tell us

The abstract does not establish complete allocation methods or denominators. Receptor expression is not evidence of fewer diabetic complications.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial
Mansour A et al. · European journal of nutrition · 2025
Tier 2
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes
Nikseresht M et al. · Physiological reports · 2024
Tier 2
Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
Panigrahi A et al. · BMC endocrine disorders · 2023
Tier 2
Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
Rondanelli M et al. · European review for medical and pharmacological sciences · 2023
Tier 2
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
Ruiz-Herrera VV et al. · International journal of STD & AIDS · 2023

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology